about
Irinotecan-induced mucositis is associated with changes in intestinal mucinsPro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositisHost-microbe cross talk in cancer therapy.Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrheaRadiation therapy-induced mucositis: relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2.The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs.Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model.Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change.Chemotherapy-induced diarrhoea.Chemotherapy-induced mucositis: the role of mucin secretion and regulation, and the enteric nervous system.Emerging evidence on the pathobiology of mucositis.Microbiota and their role in the pathogenesis of oral mucositis.The role of oral flora in the development of chemotherapy-induced oral mucositis.Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis.5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro.Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity.Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis.Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson's disease.Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.Selection of Housekeeping Genes for Gene Expression Studies in a Rat Model of Irinotecan-Induced MucositisThe potential successes and challenges of targeted anticancer therapiesAdvances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal MucositisMatrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivoVascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicityLong-term mucosal injury and repair in a murine model of pelvic radiotherapyThe pathogenesis of mucositis: updated perspectives and emerging targetsSystematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelinesIrinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat modelHighlight article: Current evidence for vitamin D in intestinal function and diseaseEditorial: Knowledge of gastrointestinal toxicity mechanisms is paving the way for improved assessment and management of patient supportive careIrinotecan-Induced Mucositis Is Associated with Goblet Cell Dysregulation and Neural Cell Damage in a Tumour Bearing DA Rat Model
P50
Q28577295-57B1E8BF-D1C3-428E-8983-74CEB5C73032Q33753588-C75B5DF5-4729-42CE-8014-6E94C6FFB695Q35600986-25655031-2655-4E12-BDD4-39F6F1649836Q36171894-E1E05928-372B-4A0F-B063-29571D7F2DBEQ36384340-D503E15A-4D8D-47F8-91B0-FB6F82ED37EAQ36625759-009E552A-AC6B-44F6-AE2D-94DEBCC0BD91Q36824342-A72BBEF5-D98A-4D26-B725-29F2C81F82C8Q37071033-DE5E1601-4280-4E0E-AE35-CC546B91DA70Q37286722-9AF33496-AAC7-4932-8221-76A3F8127373Q37370237-8D97DBA4-54E9-49C6-9DA8-722FEEA73DEFQ37443599-1EF99EAF-B474-4769-9A9E-096B5B98B4F8Q38119360-BC1EC642-FE5A-42E0-ABD6-1C0D3E0A538EQ38120647-2618F243-1684-4ACA-98F0-DD771DB11289Q38181186-D6B01FF9-3D00-4D4D-96F1-43A2FCB1F935Q38185099-DA633C57-AB17-40A1-8E3C-E3545C5EA478Q42113023-2DC61B36-BDFE-4C41-BE8B-471372CDE280Q42947782-843243EC-720F-475D-8566-7A1DF847D2FEQ43185407-608243E8-FAD8-418E-9F9A-2D1DAD066A82Q43274557-1DF31A1C-E9C4-44B2-A3C6-67A37358278CQ46142208-C9FE27B0-18BF-41D6-AB83-59EF7E14E053Q46257516-49E55282-5928-426A-B3DF-480EF2C05A9BQ46693516-C4FD333A-2805-45DD-8AC7-A7B427CE14F2Q47866555-7528C4FE-EB5A-4F32-A1F8-94243E110C60Q50540999-550F54FD-2464-4BB3-9385-4726A0E07DB9Q51113894-A74C13C6-DA6F-4829-98AD-229D86257829Q51748756-0CF552B9-CC70-477E-9499-F14D4B21955BQ52374726-A182F361-9A45-4DC3-9604-F576E4352DAFQ54335490-30651AAF-4E0F-478F-9F4A-C38338E7AC9BQ61459872-BB3318AB-3CD0-4329-BA14-DF943D10D876Q82240574-5D785651-AE4F-435E-923F-CD64718693E7Q88305051-07414827-9B33-4D1C-A8A0-16084ABC70ACQ88651392-05560F9E-1021-4345-83BE-AE3C0877F976Q88944452-23EB90CA-3093-4F17-8F88-22C8D80E5265Q90262379-464C53CD-5AA3-496B-AE6D-27D2C8CBBE8DQ91728596-A5993E61-7BE7-48D4-9B51-F508DADB5F8FQ91728608-269608DC-E588-457A-8C7C-13356960179BQ91992962-1C958AF8-6D36-41CC-97DA-54280BD25983Q92317157-16193FA7-D59A-4610-925E-6DDBE994D8F7Q92442052-DB8214C6-97C1-4763-BC29-A188F2714D68Q92664566-ABF8FD2E-93B6-48E1-9D75-F9373C9FDCE5
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3245-5360
@en
name
Andrea Stringer
@ast
Andrea Stringer
@en
Andrea Stringer
@es
Andrea Stringer
@nl
type
label
Andrea Stringer
@ast
Andrea Stringer
@en
Andrea Stringer
@es
Andrea Stringer
@nl
prefLabel
Andrea Stringer
@ast
Andrea Stringer
@en
Andrea Stringer
@es
Andrea Stringer
@nl
P106
P1153
15729767300
P31
P496
0000-0003-3245-5360